A 6-year-old boy presents with severe pruritus and lichenified plaques over the antecubital and popliteal fossae for the past 3 months. He has a personal history of allergic rhinitis and a family history of asthma. Skin prick testing shows sensitization to dust mites and pollen. Topical emollients and low-potency corticosteroids have provided only partial relief. What is the most appropriate next step in management?

Explanation

## Clinical Assessment This child presents with moderate-to-severe atopic dermatitis (AD) with: - Lichenification (chronic inflammation) - Inadequate response to topical corticosteroids alone - Classic distribution (flexural surfaces) - Atopic background (allergic rhinitis, family history of asthma) ## Management Escalation in Atopic Dermatitis | Severity | First-Line | Second-Line | Third-Line | |----------|-----------|------------|------------| | **Mild** | Emollients + low-potency TCS | Mid-potency TCS | Topical calcineurin inhibitors | | **Moderate** | Mid-potency TCS + emollients | Topical calcineurin inhibitors | Systemic agents (JAK inhibitors, biologics) | | **Severe** | High-potency TCS + emollients | Systemic corticosteroids (short-term) | Dupilumab, cyclosporine, JAK inhibitors | **Key Point:** Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are second-line agents for moderate AD that has failed to respond adequately to topical corticosteroids. They are particularly valuable in children because they avoid the skin atrophy risk of prolonged potent corticosteroid use, especially on sensitive areas (face, neck, intertriginous zones). ## Why Tacrolimus 0.03% Is Correct 1. **Indication met:** Moderate AD unresponsive to topical corticosteroids alone 2. **Age-appropriate:** The 0.03% concentration is the pediatric formulation 3. **Safety profile:** No systemic absorption; avoids corticosteroid-induced atrophy 4. **Evidence-based:** Recommended by AAD, EADV, and Indian Academy of Dermatology guidelines for this exact scenario 5. **Continued emollients:** Essential adjunct—never stop emollients in AD **Clinical Pearl:** Tacrolimus is not a first-line steroid-sparing agent in mild disease, but becomes the logical next step when low-to-mid potency topical corticosteroids prove insufficient. It works by inhibiting calcineurin, suppressing T-cell activation without causing skin atrophy. **High-Yield:** In children with moderate AD and inadequate TCS response, topical calcineurin inhibitors are preferred over escalating to systemic corticosteroids because they avoid systemic side effects and long-term complications of oral steroids (growth suppression, immunosuppression).